Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.

Public rows: 1,681
Generated: 2026-09-12
Schema version: source-consensus/2

Coverage

What this run contains

Compared medicine fields: 1,681
Agree: 1,282
Differ: 0
Not comparable: 12
Insufficient context: 387
Fields represented: 5; bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
Only the recorded fields and source documents in this snapshot are compared.
A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b

The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0

Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a

Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

Field	Type	Meaning
medicineSlug	string	Stable RNAWiki medicine route key.
field	string	Recorded pharmacokinetic field being compared.
comparisonState	string	agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasons	string[]	Deterministic codes explaining the state.
documentsExamined	number	Recorded source documents considered for the field.
sourceCount	number	Recorded source readings represented.
agreementRate	number	Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readings	consensus-reading[]	Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Showing 101–110 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

Projected row 101
Medicine slug
anidulafungin
Compared field
halfLife
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
2
Source count
2
Agreement rate
1
Recorded readings
1. 40–50 hours
  Numeric value
  40
  Unit
  hours
  Source records
  2
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 2 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a88d9010-55fb-4a02-baff-042cd27688ea (opens source in a new tab)
  Anidulafungin label
  Version not recorded · Effective date not recorded
  (10.8) CL [L/h] 0.84 (13.5) 0.94 (24.0) 0.78 (11.3) t 1/2 [h] 43.2 (17.7) 52.0 (11.7) 50.3 (9.7) The clearance of anidulafungin is about 1 L/h and anidulafungin has a terminal elimination half-life of 40–50 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d138ab10-1ed9-44be-8d81-49dda1e434ac (opens source in a new tab)
  Anidulafungin label
  Version not recorded · Effective date not recorded
  (10.8) CL [L/h] 0.84 (13.5) 0.94 (24.0) 0.78 (11.3) t 1/2 [h] 43.2 (17.7) 52.0 (11.7) 50.3 (9.7) The clearance of anidulafungin is about 1 L/h and anidulafungin has a terminal elimination half-life of 40–50 hours.
Projected row 102
Medicine slug
anidulafungin
Compared field
volumeOfDistribution
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
2
Source count
2
Agreement rate
1
Recorded readings
1. 30–50 L
  Numeric value
  30
  Unit
  L
  Source records
  2
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 2 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a88d9010-55fb-4a02-baff-042cd27688ea (opens source in a new tab)
  Anidulafungin label
  Version not recorded · Effective date not recorded
  Distribution The pharmacokinetics of anidulafungin following IV administration are characterized by a short distribution half-life (0.5–1 hour) and a volume of distribution of 30–50 L that is similar to total body fluid volume.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d138ab10-1ed9-44be-8d81-49dda1e434ac (opens source in a new tab)
  Anidulafungin label
  Version not recorded · Effective date not recorded
  Distribution The pharmacokinetics of anidulafungin following IV administration are characterized by a short distribution half-life (0.5–1 hour) and a volume of distribution of 30–50 L that is similar to total body fluid volume.
Projected row 103
Medicine slug
apixaban
Compared field
bioavailability
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
11
Source count
11
Agreement rate
1
Recorded readings
1. 50%
  Numeric value
  50
  Unit
  %
  Source records
  11
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 11 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:33a9046a-41cc-46c1-becc-2ff4d7d71538 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of ELIQUIS.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:1523ab32-2c2c-6501-e063-6394a90aa0b3 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of ELIQUIS.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:41a133ef-e461-48ad-8221-b735bdd0ec25 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of ELIQUIS.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:396912c0-9f68-47ed-ba3f-8d9ace755a48 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of apixaban tablets.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:33752f5d-2ca7-45c0-8292-b54742219b97 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of ELIQUIS.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:095a08ac-cf0e-497e-a682-ddef38d6b29c (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of apixaban.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:19a60552-374d-4b8b-a8ce-ceae252ea5ba (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of apixaban.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a454cd24-0c6d-46e8-b1e4-197388606175 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of ELIQUIS.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:7be1f4c1-bb2f-4ded-ae9a-515d2a22f93e (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of ELIQUIS.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2f47aa0e-0235-4220-85dd-dfcb8ad0d009 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of ELIQUIS.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:fd383ae7-1e34-44ef-b8f1-ca6906dfbcef (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of ELIQUIS.
Projected row 104
Medicine slug
apixaban
Compared field
halfLife
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
11
Source count
11
Agreement rate
1
Recorded readings
1. 12 hours
  Numeric value
  12
  Unit
  hours
  Source records
  11
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 11 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:33a9046a-41cc-46c1-becc-2ff4d7d71538 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:1523ab32-2c2c-6501-e063-6394a90aa0b3 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:41a133ef-e461-48ad-8221-b735bdd0ec25 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:396912c0-9f68-47ed-ba3f-8d9ace755a48 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:33752f5d-2ca7-45c0-8292-b54742219b97 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:095a08ac-cf0e-497e-a682-ddef38d6b29c (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:19a60552-374d-4b8b-a8ce-ceae252ea5ba (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a454cd24-0c6d-46e8-b1e4-197388606175 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:7be1f4c1-bb2f-4ded-ae9a-515d2a22f93e (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2f47aa0e-0235-4220-85dd-dfcb8ad0d009 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:fd383ae7-1e34-44ef-b8f1-ca6906dfbcef (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.
Projected row 105
Medicine slug
apixaban
Compared field
proteinBinding
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
11
Source count
11
Agreement rate
1
Recorded readings
1. 87%
  Numeric value
  87
  Unit
  %
  Source records
  11
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 11 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:33a9046a-41cc-46c1-becc-2ff4d7d71538 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Distribution Plasma protein binding in humans is approximately 87%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:1523ab32-2c2c-6501-e063-6394a90aa0b3 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Distribution Plasma protein binding in humans is approximately 87%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:41a133ef-e461-48ad-8221-b735bdd0ec25 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Distribution Plasma protein binding in humans is approximately 87%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:396912c0-9f68-47ed-ba3f-8d9ace755a48 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Distribution Plasma protein binding in humans is approximately 87%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:33752f5d-2ca7-45c0-8292-b54742219b97 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Distribution Plasma protein binding in humans is approximately 87%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:095a08ac-cf0e-497e-a682-ddef38d6b29c (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Distribution Plasma protein binding in humans is approximately 87%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:19a60552-374d-4b8b-a8ce-ceae252ea5ba (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Distribution Plasma protein binding in humans is approximately 87%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a454cd24-0c6d-46e8-b1e4-197388606175 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Distribution Plasma protein binding in humans is approximately 87%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:7be1f4c1-bb2f-4ded-ae9a-515d2a22f93e (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Distribution Plasma protein binding in humans is approximately 87%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2f47aa0e-0235-4220-85dd-dfcb8ad0d009 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Distribution Plasma protein binding in humans is approximately 87%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:fd383ae7-1e34-44ef-b8f1-ca6906dfbcef (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  Distribution Plasma protein binding in humans is approximately 87%.
Projected row 106
Medicine slug
apixaban
Compared field
volumeOfDistribution
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
11
Source count
11
Agreement rate
1
Recorded readings
1. 21 liters
  Numeric value
  21
  Unit
  L
  Source records
  11
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 11 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:33a9046a-41cc-46c1-becc-2ff4d7d71538 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  The volume of distribution (Vss) is approximately 21 liters.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:1523ab32-2c2c-6501-e063-6394a90aa0b3 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  The volume of distribution (Vss) is approximately 21 liters.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:41a133ef-e461-48ad-8221-b735bdd0ec25 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  The volume of distribution (Vss) is approximately 21 liters.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:396912c0-9f68-47ed-ba3f-8d9ace755a48 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  The volume of distribution (Vss) is approximately 21 liters.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:33752f5d-2ca7-45c0-8292-b54742219b97 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  The volume of distribution (Vss) is approximately 21 liters.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:095a08ac-cf0e-497e-a682-ddef38d6b29c (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  The volume of distribution (Vss) is approximately 21 liters.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:19a60552-374d-4b8b-a8ce-ceae252ea5ba (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  The volume of distribution (Vss) is approximately 21 liters.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a454cd24-0c6d-46e8-b1e4-197388606175 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  The volume of distribution (Vss) is approximately 21 liters.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:7be1f4c1-bb2f-4ded-ae9a-515d2a22f93e (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  The volume of distribution (Vss) is approximately 21 liters.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2f47aa0e-0235-4220-85dd-dfcb8ad0d009 (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  The volume of distribution (Vss) is approximately 21 liters.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:fd383ae7-1e34-44ef-b8f1-ca6906dfbcef (opens source in a new tab)
  Apixaban label
  Version not recorded · Effective date not recorded
  The volume of distribution (Vss) is approximately 21 liters.
Projected row 107
Medicine slug
apomorphine
Compared field
volumeOfDistribution
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
2
Source count
2
Agreement rate
1
Recorded readings
1. 218 L
  Numeric value
  218
  Unit
  L
  Source records
  2
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 2 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:aedf70e4-1949-44bc-bf1b-0f282c4f0705 (opens source in a new tab)
  Apomorphine label
  Version not recorded · Effective date not recorded
  Mean (range) apparent volume of distribution was 218 L (123 L to 404 L).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f3552b6e-5ae7-4993-aa1a-e399c4a7080a (opens source in a new tab)
  Apomorphine label
  Version not recorded · Effective date not recorded
  Mean (range) apparent volume of distribution was 218 L (123 to 404 L).
Projected row 108
Medicine slug
aprepitant
Compared field
bioavailability
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
8
Source count
6
Agreement rate
1
Recorded readings
1. 60 to 65%
  Numeric value
  60
  Unit
  %
  Source records
  6
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 6 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f58b8944-93ee-4be1-a238-cc0061ddd93a (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  At the dose range of 80 to 125 mg, the mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d72e0e10-4557-41b0-b65d-d395468cad19 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  At the dose range of 80 to 125 mg, the mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:377c3ecb-fdec-dde4-e063-6294a90a29bd (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  At the dose range of 80 to 125 mg, the mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:696f9e80-9cae-403b-de9e-078343ce4713 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  At the dose range of 80 to 125 mg, the mean absolute oral bioavailability of EMEND is approximately 60 to 65%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  At the dose range of 80 to 125 mg, the mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:af9b6086-4bf2-472c-8740-4134eaaebace (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  At the dose range of 80 to 125 mg, the mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.
Projected row 109
Medicine slug
aprepitant
Compared field
halfLife
Comparison state
insufficient_context
Reason codes
- STRUCTURED_CONTEXT_MISSING
Documents examined
8
Source count
8
Agreement rate
0.875
Recorded readings
1. 9 to 13 hours
  Numeric value
  9
  Unit
  hours
  Source records
  7
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 7 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:4c218d3a-a508-4abc-9ed8-a6e8e191d1b4 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The apparent terminal half-life ranged from approximately 9 to 13 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f58b8944-93ee-4be1-a238-cc0061ddd93a (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The apparent terminal half-life ranged from approximately 9 to 13 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d72e0e10-4557-41b0-b65d-d395468cad19 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The apparent terminal half-life ranged from approximately 9 to 13 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:377c3ecb-fdec-dde4-e063-6294a90a29bd (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The apparent terminal halflife ranged from approximately 9 to 13 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:696f9e80-9cae-403b-de9e-078343ce4713 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The apparent terminal half-life ranged from approximately 9 to 13 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The apparent terminal half-life ranged from approximately 9 to 13 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:af9b6086-4bf2-472c-8740-4134eaaebace (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The apparent terminal halflife ranged from approximately 9 to 13 hours.
2. 12 hours
  Numeric value
  12
  Unit
  hours
  Source records
  1
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 1 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d1b111eb-659a-496b-a86a-8f0fa370f147 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The mean terminal half-life of aprepitant following administration of APONIVE was 12 hours.
Projected row 110
Medicine slug
aprepitant
Compared field
volumeOfDistribution
Comparison state
insufficient_context
Reason codes
- STRUCTURED_CONTEXT_MISSING
Documents examined
8
Source count
8
Agreement rate
0.875
Recorded readings
1. 70 L
  Numeric value
  70
  Unit
  L
  Source records
  7
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 7 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:4c218d3a-a508-4abc-9ed8-a6e8e191d1b4 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f58b8944-93ee-4be1-a238-cc0061ddd93a (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d72e0e10-4557-41b0-b65d-d395468cad19 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:377c3ecb-fdec-dde4-e063-6294a90a29bd (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:696f9e80-9cae-403b-de9e-078343ce4713 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:af9b6086-4bf2-472c-8740-4134eaaebace (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
2. 72 L
  Numeric value
  72
  Unit
  L
  Source records
  1
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 1 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d1b111eb-659a-496b-a86a-8f0fa370f147 (opens source in a new tab)
  Aprepitant label
  Version not recorded · Effective date not recorded
  The mean volume of distribution following APONVIE administration was approximately 72 L in healthy subjects.

Access

Query or download the projection

View this filtered page as JSON Download up to 200 filtered CSV rows

GET /api/datasets/source-consensus?limit=10&offset=100

Allowed query parameters

q: Case-insensitive text search over the public fields named for this dataset.
state: Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field: Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset: Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy